AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01332318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP13512
Description: XP13512 once daily for 16 days
Study NCT01332318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: one 50 mg dose of diphenhydramine (DPH) on day 16
Study NCT01332318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: XP13512 placebo once daily for 16 days
Study NCT01332318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: XP13512 placebo once daily for 16 days
Study NCT01721759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01657552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Each tablet contains 100 mg of Eltrombopag (Dose 200 mg)
Study NCT01657552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Each capsule contains 200 mg of Boceprevir (Dose 800 mg)
Study NCT01657552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Each tablet contains 375 mg of Telaprevir (Dose 750 mg)
Study NCT02544633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD265
Description: MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor
Study NCT01217203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2101 combined to lenalidomide
Description: Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day)~Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD)
Study NCT04242966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
Study NCT04242966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher Protein/Amino Acid Group
Description: Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
Study NCT04242966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound measure
Description: Patients will undergo the ultrasound measures at baseline (within 24 hours of randomization, day 10 days post randomization (if still in hospital) and just prior to hospital discharge. In the event that hospital discharge is prior to day 10, the day 10 measure will not be done.
Study NCT02429401 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-adapted brief motivational interview
Description: 1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
Study NCT02429401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adapted brief motivational interview
Description: Addresses impact of acculturative stress and drinking norms based on screening results and 1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
Study NCT03154528 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum vitamin D level by ELISA
Description: The study will include 60 patients with androgenetic alopecia (30 males \& 30 females) and 30 age and sex-matched healthy volunteers. Study subjects will be recruited from the Dermatology Outpatients' Clinic, Assiut University Hospitals, Assiut, Egypt. Informed consent will be obtained from all subjects
Study NCT00071409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INGAP-Peptide
Description: 1.5 mL, once daily, self-administered SC injection for 90 days
Study NCT00071409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1.5 mL, once daily, self-administered SC injection for 90 days
Study NCT02182011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Study NCT03877718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 5: Promethazine HCl 37.5 mg
Description: One capsule of promethazine HCl 37.5 mg
Study NCT02182011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Study NCT02182011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Streptokinase
Study NCT00802750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric POBE
Description: LoFric POBE, Nelaton 40 cm, CH 12 with new solvent. Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters.
Study NCT00802750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric POBE
Description: Unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with new solvent Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters.
Study NCT03094520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS)
Study NCT03094520 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-tDCS
Description: sham stimulation
Study NCT03973437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial inteligence associated ulcerative colitis severity scoring system
Description: Patients in this group go through a flexible colonoscopy under the AI monitoring device. During the withdrawal process, inflammatory lesions are detected by AI-associated scoring system. Pictures are automatically captured and analyzed by the computer. The Mayo ES and UCEIS sores will be calculated and presented on a second screen, providing a reference for the physician to evaluate the disease severity and mucosal healing stage of the patient. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
Study NCT03877718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One capsule of placebo
Study NCT03973437 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional human scoring
Description: Patients in this group go through a conventional colonoscopy without the AI monitoring device. During the withdrawal process, physician evaluates the disease severity and mucosal healing stage of the patient according to his personal experience. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
Study NCT04481048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Eight (8) weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC).
Study NCT04481048 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eight (8) weeks of treatment with placebo.
Study NCT00421252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel 600 mg
Description: Clopidogrel load > 2hrs pre-angiography
Study NCT00421252 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: arterial access sheath
Description: randomize to 5Fr vs 6Fr
Study NCT04679467 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU sphere
Description: TYR sphere is a powdered, low phenylalanine and tyrosine protein substitute, containing a balanced mix of casein glycomacropeptide (cGMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP); Docosahexaenoic acid (DHA). It contains sugars and sweetener.~The product is designed to be prescribed based on its protein content, not its energy content.
Study NCT03335358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic (couples-based) positive psychology intervention
Description: Self-administered behavioral intervention in which participants complete at least 2 activities alone and 2 together each week for 8 weeks. Positive psychology activities include expressing gratitude, practicing acts of kindness, fostering relationships, working toward a goal, focusing on the positive, spirituality, and savoring.
Study NCT03335358 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dyadic (couples-based) positive psychology intervention
Description: Self-administered behavioral intervention in which participants complete at least 2 activities alone and 2 together each week for 8 weeks. Positive psychology activities include expressing gratitude, practicing acts of kindness, fostering relationships, working toward a goal, focusing on the positive, spirituality, and savoring.
Study NCT03726346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toffee Full Face Mask
Description: Participants will be placed on this arm for a total of 14+- 4 days from visit 2. Participants will be using the Toffee mask during this treatment arm.
Study NCT04307823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: 3 days per week, starting at shorter duration 5-20min and progressed to 30- 40mins.~Training% or Intensity was kept 40-70%,~Training Heart Rate (HR) was calculated through formula:~HR max HR rest\*Ex intensity + HR rest Rate of Perceived Exertion (RPE) 9-14 ON 6 -20 RPE scale The session was terminated if sustained ventricular arrhythmia, symptomatic drop in blood pressure, ST elevation, or development of severe symptoms
Study NCT04307823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill protocol and Respiratory training
Description: Treadmill protocol~Spirometry:~Volumetric exercises, using incentive Spirometer 10-15 repetitions~Slow breathing training:~5 minutes: spontaneous breathing, 4 minutes: controlled breathing (15 breaths/min) 4 minutes of controlled breathing (6 breaths/min) Treatment provided for 3 days in a week for a period of 4 weeks
Study NCT02428868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid (Exacyl®)
Description: 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later
Study NCT02428868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid (Exacyl®)
Description: 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later
Study NCT02428868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous iron (Ferroven®)
Description: 2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.
Study NCT02428868 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 20 mL saline in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
Study NCT02076152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FMISO PET
Study NCT02076152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MR scans will be performed with the same sequences and in the same order during each visit, including T1- and T2-weighted volumetric images, fluid attenuated inversion recovery (FLAIR), contrast agent enhanced T1-weighted permeability, diffusion tensor imaging (DTI), T2/T2\*-weighted perfusion scans, and MR Spectroscopy. The Autoalign package available from the manufacturer will be used to achieve the same slice prescription in the same patient at each visit. Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs.
Study NCT02076152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
Study NCT02076152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCNU
Description: A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
Study NCT02951104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Cardiac Output Monitor (USCOM) system
Study NCT02882568 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood analysis
Description: Pilot study, single center, interventional including 15 obese subjects with acute sepsis. Inflammatory and immunological tests during acute phase and one month later after a presumed return parameters at baseline
Study NCT01265069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose dual therapy
Description: rabeprazole 20mg qid,amoxicillin 750mg qid for 14days
Study NCT01265069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concomitant therapy
Description: rabeprazole 20 mg,amoxicillin 1000 mg,metronidazole 500 mg,clarithromycin 500 mg, bid for 10 days
Study NCT01572727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: intravenous paclitaxel 80 mg/m2 per week given until progression
Study NCT01572727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: intravenous paclitaxel 80 mg/m2 per week given until progression
Study NCT01572727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BKM120 matching placebo
Description: Buparlisib maching plaxcebo were supplied as 100 mg and 50 mg hard gelatin capsules.~Buparlisib placebo was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
Study NCT01572727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Buparlisib (BKM120) were supplied as 100 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
Study NCT01949480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracotomy
Study NCT01949480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracotomy
Study NCT01949480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-Assisted Thoracoscopic Surgery (VATS)
Study NCT01949480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video-Assisted Thoracoscopic Surgery (VATS)
Study NCT02020954 — intervention group
Intervention type: PROCEDURE
Intervention: ECG, echocardiography, cardiac MRI, sera biomarkers
Study NCT04556708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: salin irrigation
Description: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with saline was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
Study NCT04556708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ozonated water irrigation
Description: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with ozonated water was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
Study NCT04556708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine irrigation
Description: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with 0.12% chlorhexidine digluconate was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
Study NCT04053764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizuamb
Description: Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab
Study NCT04053764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: HU/HC (hydroxyurea/hydroxycarbamide) and/or ACE (angiotensin-converting enzyme) inhibitors and/or ARBs (angiotensin-receptor blocker)
Study NCT04053764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: HU/HC (hydroxyurea/hydroxycarbamide) and/or ACE (angiotensin-converting enzyme) inhibitors and/or ARBs (angiotensin-receptor blocker)
Study NCT03872349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids diet
Description: During 4 weeks, subjects eat a diet high in monounsaturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
Study NCT03872349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids diet
Description: During 4 weeks, subjects eat a diet high in saturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
Study NCT00402753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulatory Physical Exercise Program
Description: supervised exercise, 2 x / week
Study NCT00959517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate (AS)
Description: Recommended dosage over 3 days (for all interventions)
Study NCT00959517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulphadoxine-pyrimethamine (SP)
Study NCT00959517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Study NCT00959517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primaquine (PQ)
Study NCT04152733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: Oxygen is supplied via high flow nasal cannula. Heated air (2L/kg/min) is administered using Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand).
Study NCT01262066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifeskills Workshop Intervention
Description: Intervention participants attended 10 one-hour weekly group sessions. The content of the groups followed the LifeSkills Workshop manual and Video ( (Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
Study NCT00232804 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bx Cypher stent
Study NCT01972516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Study NCT01507870 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: onlay mesh placement
Description: prophylactic onlay mesh in patients with median laparotomy
Study NCT02025777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule Endoscopy
Study NCT04818411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy treatment with the Stabilization exercises
Description: The program was based on specific training of the transversely oriented abdominal muscles with coactivation of the lumbar multifidus at the lumbosacral region, training of the gluteus maximus, the latissimus dorsi, the oblique abdominal muscles, the erector spinae, the quadratus lumborum, and the hip adductors and abductors. Initially, we focused on the specific contraction of the transversely oriented abdominal muscles. After approximately 2 weeks, loading was progressively increased throughout the intervention period. The women were required to exercise for 30 to 60 minutes, 3 days a week, for 3-4 weeks.
Study NCT04818411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy treatment + High-velocity thrust manipulation
Description: : For high-velocity thrust technique, a modified Chicago technique was used. For this procedure, the lumbopelvic region was targeted. The side to be treated was chosen, based on the subject's report of her most symptomatic side. The physical therapist, performed passively side bend the subject toward the painful side, rotate the upper body in the direction opposite to the side bending, and then deliver a quick posterior and inferior thrust at a grade V including a small-amplitude/high-velocity therapeutic movement. A maximum of 2 attempts per side was permitted if no pop was heard following the first attempt. If the subject showed improvement of 50% or less after the first treatment, the intervention was categorized as a failure, the examination and intervention were repeated, and the subjects were asked to return 2 to 4 days later. If the subject showed greater than 50% improvement, the intervention was categorized as a success, and study participation was concluded.